Retatrutide
Retatrutide is a first-in-class triple agonist targeting GLP‑1R, GIPR, and GCGR receptors. It combines potent appetite suppression, delayed gastric emptying, enhanced insulin sensitivity, and increased energy expenditure to achieve unprecedented improvements in body weight and glycemic control. Its triple mechanism delivers greater weight loss and metabolic benefit than single or dual agonists.
| 5mg*10vials | $68 | 40mg*10vials | $260 |
| 10mg*10vials | $112 | 50mg*10vials | $310 |
| 15mg*10vials | $155 | 60mg*10vials | $370 |
| 20mg*10vials | $165 | 100mg*10vials | $430 |
| 30mg*10vials | $220 |
Product Information
What is Retatrutide?
Retatrutide is an investigational, prescription-only peptide developed by Eli Lilly and CompanyEli Lilly and Company. It is the world’s first and only triple hormone receptor agonist, designed to simultaneously activate three key metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor)Eli Lilly and Company. It is administered as a once-weekly subcutaneous injectionEli Lilly and Company.
Who is it for?
- Adults with obesity (BMI ≥ 30 kg/m²)
- Adults with overweight (BMI ≥ 27 kg/m²) plus weight-related health issues:
- High blood pressure (hypertension)
- High cholesterol (dyslipidemia)
- Fatty liver disease (MASLD)
- Obstructive sleep apnea
- Knee osteoarthritis
- Long-term chronic weight management (not short-term dieting)
How It Works
- GLP-1 Activity: Reduces hunger, slows stomach emptying, increases feelings of fullness (satiety), improves blood sugar control.
- GIP Activity: Enhances fat metabolism and insulin sensitivity.
- Glucagon (GCGR) Activity: Unique to Retatrutide — boosts resting calorie burn (energy expenditure) and accelerates fat breakdown.
Net Effect: You eat fewer calories and burn more calories — dual-action weight loss.
How to Use
- Administration: Subcutaneous injection (abdomen, thigh, or upper arm)
- Frequency: Once weekly (same day every week)
- Dose Titration (Gradual Increase):
- Week 1–4: 2 mg once weekly
- Week 5–8: 4 mg once weekly
- Week 9 onwards: 8 mg–12 mg once weekly (target/maintenance)
Effectiveness
- Weight Loss (12 mg, 68–72 weeks):
- Average: 24.2%–28.7% body weight loss (≈24–29 kg / 53–64 lbs for a 100 kg person)
- ~59% of users lost ≥25% body weight
- ~24% lost ≥35% body weight (similar to bariatric surgery results)
- Metabolic Benefits:
- Significant improvements in blood pressure, triglycerides, liver fat, and insulin sensitivity
Important Warnings & Contraindications
Do NOT use if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC)
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Are pregnant, planning pregnancy, or breastfeeding
- Have a history of severe pancreatitis
- Are allergic to Retatrutide or its ingredients
Associated Products
Related Experimental Studies
